Atara Biotherapeutics, Inc.
2659 Townsgate Road
220 articles with Atara Biotherapeutics, Inc.
This year could be the big year for the company. Its chief executive officer and president, Isaac Ciechanover, is leaving the company by June 30, but says 2019 could be transformative.
1/4/2019Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.
Atara Biotherapeutics Exclusively Licenses Mesothelin-Targeted CAR T Immunotherapy for Solid TumorsAtara Biotherapeutics Exclusively Licenses Mesothelin-Targeted� CAR T Immunotherapy for Solid Tumors
Initial results from ongoing Phase 1 study for mesothelin-targeted CAR T support activity and safety in patients with advanced solid tumors
10/15/2018Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies
Focus on multi-targeted CAR T immunotherapies for patients with acute myelogenous leukemia (AML) and B-cell malignancies
There is a new player in the southern California biotech industry. New venture firm Westlake Village BioPartners launched with a $320 million fund and a leadership well familiar with the ins and outs of the biotech and pharma world.
5/13/2018Biotech companies tapped a number of new upper management and c-suite executives last week. BioSpace put together a roundup of some of the latest appointments in the industry, which includes a number of new chief executive officers hired to helm companies.
With the J.P. Morgan Healthcare Conference now over, some analysts are looking back and picking out the "winners and losers" from the conference.
Atara Biotherapeutics Announces FDA Clearance to Proceed With Enrollment at U.S. Sites for Ongoing Global Phase I Clinical Study to Evaluate ATA188 in Patients With Progressive or Relapsing-Remitting Multiple Sclerosis
The primary objective of Atara’s ongoing Phase 1 clinical study is to assess the safety of ATA188 in patients followed for at least one year after the first dose.
The offering is expected to close on or about January 8, 2018, subject to customary closing conditions.
The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Atara Biotherapeutics Announces Initiation of Two Phase III Clinical Studies to Evaluate Tabelecleucel in Patients With Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD)
Tabelecleucel is Atara's off-the-shelf T-cell immunotherapy in development for the treatment of EBV+PTLD, as well as other EBV associated hematologic and solid tumors.
Atara Biotherapeutics to Host Corporate Update Conference Call on Friday, December 29, 2017, at 8:00 a.m. EST
A replay of the webcast will be available on the Company’s website for 90 days following the live conference call.
Atara Biotherapeutics Announces FDA Clearance to Initiate Two Phase III Clinical Studies to Evaluate Tabelecleucel in Patients With Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD)
Tabelecleucel is Atara's off-the-shelf T-cell immunotherapy in development for the treatment of EBV+PTLD.
Celgene has been unloading some of its shares in two of its investments, CRISPR Therapeutics and Atara Biotherapeutics.
Cash, cash equivalents and short-term investments as of September 30, 2017 totaled $200.2 million.
Atara Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results From a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus-Associated Cancers
The Company’s collaborating investigators at Memorial Sloan Kettering Cancer Center will present, on behalf of eight major transplant centers in the U.S.
Atara Biotherapeutics Receives Rare Pediatric Disease Designation From FDA for ATA230 for Treatment of Congenital Cytomegalovirus (CMV) Infection
The FDA grants Rare Pediatric Disease designation to drugs or biologics intended to treat serious or life-threatening rare diseases that primarily affect individuals aged from birth to 18 years and fewer than 200,000 persons in the U.S.
Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase I Study of Autologous ATA190
Six of ten progressive MS patients in the Phase 1 study of autologous ATA190 (formerly known as autologous ATA188) experienced clinical improvements.
Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (MS)
Enrollment to begin in Australia; U.S. sites expected to open in early 2018.